Please use this identifier to cite or link to this item: https://doi.org/10.1155/2013/358285
Title: Disruptions in liver function among cancer patients and patients treated with tyrosine kinase inhibiting drugs: Comparisons of two population-based databases
Authors: Landis, S.H
Nordstrom, B.L
Sansbury, L.B
Shantakumar, S 
Laurent, S.A.S
Fraeman, K.H
Nelson, J.J
Keywords: dasatinib
erlotinib
gefitinib
imatinib
lapatinib
nilotinib
adult
article
cancer patient
drug exposure
electronic medical record
female
health insurance
human
liver dysfunction
major clinical study
male
priority journal
Issue Date: 2013
Citation: Landis, S.H, Nordstrom, B.L, Sansbury, L.B, Shantakumar, S, Laurent, S.A.S, Fraeman, K.H, Nelson, J.J (2013). Disruptions in liver function among cancer patients and patients treated with tyrosine kinase inhibiting drugs: Comparisons of two population-based databases. Journal of Cancer Epidemiology 2013 : 358285. ScholarBank@NUS Repository. https://doi.org/10.1155/2013/358285
Rights: Attribution 4.0 International
Abstract: Liver toxicity is a recognized adverse event associated with small molecule tyrosine kinase inhibitors (TKIs). Electronic Medical Record (EMR) databases offer the most precise data to investigate the rate of liver function test (LFT) elevations; however, they can be limited in sample size and costly to access and analyze. Health insurance claims databases often contain larger samples sizes but may lack key health information. We evaluated the feasibility of utilizing a large claims database to calculate incidence rates (IRs) of LFT elevations among a general cohort of cancer patients and a cohort of patients treated with TKIs by comparing the results to a "gold standard" oncology-specific EMR database. IRs for the TKI cohorts were very similar between the two databases; however, IRs were higher in the EMR database for the cancer cohorts. Possible explanations for these differences include lack of specificity when defining a cancer case, poor capture of laboratory data, or inaccurate assessment of person-time in the insurance claims database. This study suggests that insurance claims data may provide reliable results when investigating liver toxicities associated with oncology drug exposure; however, there are limitations when assessing laboratory outcomes for cohorts defined solely by disease status. © 2013 Sarah H. Landis et al.
Source Title: Journal of Cancer Epidemiology
URI: https://scholarbank.nus.edu.sg/handle/10635/181816
ISSN: 16878558
DOI: 10.1155/2013/358285
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2013_358285.pdf1.34 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

3
checked on Oct 22, 2021

Page view(s)

77
checked on Oct 21, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons